Covered recipient · General Payments record
ROBERT JAMES FOX
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2018–2024
$284,022.04
- Reported across 226 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $16,147.50 | 8 |
| Food and Beverage | $419.76 | 6 |
| Travel and Lodging | $274.64 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Biogen, Inc. | $6,507.50 | 2 |
| F. Hoffmann-La Roche AG | $5,859.24 | 5 |
| SANOFI-AVENTIS U.S. LLC | $2,920.00 | 2 |
| E.R. Squibb & Sons, L.L.C. | $1,200.00 | 1 |
| Alexion Pharmaceuticals, Inc. | $141.17 | 2 |
| TG THERAPEUTICS, INC. | $137.52 | 2 |
| EMD Serono, Inc. | $76.47 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $90.17 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1094029408 | CMS |
| Alexion Pharmaceuticals, Inc. | $51.00 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1094019694 | CMS |
| Biogen, Inc. | $2,740.00 | 03/06/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1104844194 | CMS |
| Biogen, Inc. | $3,767.50 | 11/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1104839476 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,200.00 | 06/04/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101749801 | CMS |
| EMD Serono, Inc. | $76.47 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120245009 | CMS |
| F. Hoffmann-La Roche AG | $690.00 | 04/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1133098140 | CMS |
| F. Hoffmann-La Roche AG | $2,760.00 | 05/16/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1133098144 | CMS |
| F. Hoffmann-La Roche AG | $64.60 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133098148 | CMS |
| F. Hoffmann-La Roche AG | $2,070.00 | 09/16/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1133098152 | CMS |
| F. Hoffmann-La Roche AG | $274.64 | 09/16/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1133098156 | CMS |
| SANOFI-AVENTIS U.S. LLC | $1,752.00 | 03/21/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1139680683 | CMS |
| SANOFI-AVENTIS U.S. LLC | $1,168.00 | 10/29/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1139680791 | CMS |
| TG Therapeutics, Inc. | $115.41 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136890084 | CMS |
| TG Therapeutics, Inc. | $22.11 | 06/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136890072 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.